Tibet Weixinkang Medicine Co., Ltd. (SHA:603676)
11.18
-0.25 (-2.19%)
Feb 4, 2026, 1:14 PM CST
Tibet Weixinkang Medicine Revenue
Tibet Weixinkang Medicine had revenue of 276.24M CNY in the quarter ending September 30, 2025, a decrease of -23.50%. This brings the company's revenue in the last twelve months to 1.17B, down -6.97% year-over-year. In the year 2024, Tibet Weixinkang Medicine had annual revenue of 1.30B, down -1.69%.
Revenue (ttm)
1.17B
Revenue Growth
-6.97%
P/S Ratio
4.08
Revenue / Employee
1.70M
Employees
689
Market Cap
4.76B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.30B | -22.41M | -1.69% |
| Dec 31, 2023 | 1.32B | -75.89M | -5.43% |
| Dec 31, 2022 | 1.40B | 364.92M | 35.31% |
| Dec 31, 2021 | 1.03B | 317.96M | 44.43% |
| Dec 31, 2020 | 715.67M | -25.30M | -3.41% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jinling Pharmaceutical Company | 3.13B |
| Jinhe Biotechnology CO., LTD. | 2.75B |
| Luoxin Pharmaceuticals Group Stock | 2.49B |
| Yabao Pharmaceutical Group | 2.27B |
| Guizhou Sanli Pharmaceutical Co.,Ltd | 1.74B |
| LanZhou Foci Pharmaceutical | 895.75M |
| Newland Pharmaceutical | 670.43M |
| Shanghai Xiao Fang Pharmaceutical | 504.59M |